Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.79 -0.01 (-0.04%)
Official Closing Price Updated: 7:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
News headline image
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application ↗
Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval. 
Via Benzinga
News headline image
Recent Filing Shows That Rep. Carol Miller Sold Over $60K Worth of Pfizer Stock ↗
A August filing shows that Representative Carol Miller reported a sale in Pfizer (NYSE:PFE), valued between $60,004 and $200,000. The transaction date is listed as March 10, 2025, with the report... 
Via Benzinga
News headline image
Vanguard Is "Cautious" on U.S. Growth Stocks. These 2 Value ETFs Could Be Smarter Buys for Long-Term Investors. ↗
In the next 10 years, underrated sectors and undervalued companies might beat the biggest names of the AI trade. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
Most active S&P500 stocks in Monday's session ↗
Via Chartmill
Most active S&P500 stocks in Friday's session ↗
Via Chartmill
News headline image
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
From Pfizer Inc.
Via Business Wire
News headline image
Valneva Q2 Earnings Call Highlights ↗
Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and... 
Via MarketBeat
Topics Earnings
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
News headline image
2 Large-Cap Stocks for Long-Term Investors and 1 We Avoid
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
Which S&P500 stocks are the most active on Wednesday? ↗
Via Chartmill
News headline image
Rigel (RIGL) Q2 2026 Earnings Call Transcript ↗
VEPPANU launch and R289 data readouts drive second-half priorities. 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock ↗
This problem has a solution, and Pfizer is implementing it. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Arvinas (ARVN) Q2 2026 Earnings Call Transcript ↗
VEPPANU's FDA approval and $50 million Pfizer milestone fuel record net income. 
Via The Motley Fool
Topics Earnings
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? ↗
Both of these stocks pay more than double the S&P 500 average of 1.1%. 
Via The Motley Fool
Topics Stocks
News headline image
BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗
COVID vaccine demand weakens as BioNTech pivots to oncology with promising clinical data. 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer (PFE) Q2 2026 Earnings Call Transcript ↗
Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings. 
Via The Motley Fool
Topics Earnings
News headline image
5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performanc... 
Via StockStory
Topics Earnings
News headline image
BridgeBio Pharma Q2 Earnings Call Highlights ↗
BridgeBio Pharma (NASDAQ:BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review... 
Via MarketBeat
Topics Earnings
News headline image
Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner? ↗
The stock's 6.4% yield is attractive, but it comes with risk. 
Via The Motley Fool
News headline image
Global Precision Medicine Market: Size, Trends, Drivers, and Forecast 2026-2033 ↗
The Precision Medicine industry is rapidly transforming healthcare delivery by enabling personalized treatment strategies tailored to genetic, environmenta 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗
Berobenatide is one of the keys to Pfizer's future. 
Via The Motley Fool
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations
Animal health company Zoetis (NYSE:ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The comp... 
Via StockStory
News headline image
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion.... 
Via StockStory
News headline image
3 Beaten-Down Stocks to Hold for the Next 10 Years ↗
Don't let their recent poor performances chase you away. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Q2 Earnings Call Highlights ↗
Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue... 
Via MarketBeat
Topics Earnings Intellectual Property
S&P 500 Prints Fresh Record As Chips Rip And Hormuz Talks Crack The Oil Trade ↗
Via Chartmill
Topics Stocks
News headline image
PFE Q2 Deep Dive: New Products Offset COVID Decline, R&D Pipeline Expands
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.